

+

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

1

of

1

Application Number

Unassigned

Filing Date

March 29, 2004

First Named Inventor

Mirna Urquidi-Macdonald

Group Art Unit

Unassigned

Examiner Name

Unassigned

Attorney Docket Number

402869/NIH

[illegible][illegible]

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
JD	A 3	Abernethy et al., <i>Clinical Pharmacology & Therapeutics</i> , 73(2):51, PII-85		
	A 4	Urquidi-Macdonald et al., <i>Clinical Pharmacology & Therapeutics</i> , 75(1):60-69 (2004)		
	A 5	Mirna Urquidi-Macdonald, "Fast-BP", 6 th WSEAS Proceedings, July 7-14, 2002, Crete, Greece		
g	A 6	<i>News Penn State</i> , "New Computer-Aided Approach Tailors Drug Dose to Patient Needs", March 15, 2004		

Examiner Signature

Date Considered

8/2/96

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).